Last reviewed · How we verify

An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Autism

NCT01502488 Phase 1/Phase 2 WITHDRAWN

The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Autism.

Details

Lead sponsorAgeless Regenerative Institute
PhasePhase 1/Phase 2
StatusWITHDRAWN
Start date2016-10
Completion2018-01

Conditions

Interventions

Primary outcomes

Countries

United States